Cathay Biotech Inc

Cathay Biotech Inc

  • Price (CNY)100.98
  • Today's Change-3.75 / -3.58%
  • Shares traded1.20m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 27 2021 08:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cathay Biotech Inc is a company engaged in research, development, production and sales of biobased materials. The Company's primary products are biological long-chain dibasic acids, including lauric acid and brazilian acid, which are used in long-chain polyamides, fragrances, hot melt adhesives, lubricants, powder coatings and other areas. The Company sells its products to both domestic and international markets, including the United States, Japan and Europe.

  • Revenue in CNY (TTM)1.58bn
  • Net income in CNY480.68m
  • Incorporated2000
  • Employees1.31k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Red Avenue New Materials Group Co Ltd2.16bn492.35m37.71bn609.0076.9014.08--17.430.83680.83683.684.570.43166.583.583,552,372.0010.1512.6917.0220.8734.0735.0623.5217.411.28--0.430134.19-7.345.5724.1739.8973.35--
Far Eastern New Century Corp48.67bn2.14bn39.43bn28.56k17.170.82684.240.81011.861.8642.2238.580.33766.806.43--2.242.733.334.0020.3020.596.656.670.7255--0.511378.76-17.34-1.05-24.880.0696-4.166.19
Inner Mngl Jnzhng Eng & CmcI Gp Co Ltd15.32bn5.29bn42.70bn5.51k8.071.95--2.790.6270.6271.822.590.400117.9317.992,780,179.0013.7910.7320.7213.8431.2138.6834.4728.491.01--0.253254.4650.9925.0993.2441.80-6.1497.44
Indorama Ventures PCL66.51bn1.40bn42.86bn23.90k30.631.607.410.64441.271.2760.1424.260.69554.518.0114,125,860.001.814.332.606.0815.6414.432.604.510.55992.330.597235.07-6.017.15-61.04-22.0011.897.84
Cathay Biotech Inc1.58bn480.68m43.64bn1.31k85.444.14--27.641.231.234.0425.270.16821.057.011,206,936.005.12--6.08--47.88--30.43--20.88--0.00---21.87---4.43------
Kingfa Sci&Tech Co Ltd38.58bn5.21bn52.06bn10.26k9.993.34--1.352.022.0214.996.061.196.4810.573,761,182.0016.106.7024.2410.5425.3017.8713.575.951.2112.010.464843.1219.7217.46268.6445.1612.7543.10
Data as of Jul 27 2021. Currency figures normalised to Cathay Biotech Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.93%Per cent of shares held by top holders
HolderShares% Held
Aegon-Industrial Fund Management Co., Ltd.as of 31 Dec 20201.59m3.97%
China Universal Asset Management Co., Ltd.as of 31 Dec 2020301.60k0.75%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 202094.56k0.24%
HuaAn Fund Management Co., Ltd.as of 31 Dec 202077.29k0.19%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 202064.83k0.16%
Krane Funds Advisors LLCas of 08 Jul 202153.06k0.13%
Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 202051.11k0.13%
Yinhua Fund Management Co., Ltd.as of 31 Dec 202050.58k0.13%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 202049.87k0.12%
Rongtong Fund Management Co., Ltd.as of 31 Dec 202047.55k0.12%
More ▼
Data from 31 Dec 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.